These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19914762)

  • 1. Impaired awareness of movement disorders in Parkinson's disease.
    Amanzio M; Monteverdi S; Giordano A; Soliveri P; Filippi P; Geminiani G
    Brain Cogn; 2010 Apr; 72(3):337-46. PubMed ID: 19914762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
    Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease.
    Amanzio M; Palermo S; Zibetti M; Leotta D; Rosato R; Geminiani G; Lopiano L
    Brain Cogn; 2014 Oct; 90():135-41. PubMed ID: 25058494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Self-awareness of deficits in Huntington's and Parkinson's disease].
    Sitek EJ; Sławek J; Wieczorek D
    Psychiatr Pol; 2008; 42(3):393-403. PubMed ID: 19899567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications.
    Solla P; Cannas A; Floris GL; Orofino G; Costantino E; Boi A; Serra C; Marrosu MG; Marrosu F
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1009-13. PubMed ID: 21324349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
    Stacy M; Bowron A; Guttman M; Hauser R; Hughes K; Larsen JP; LeWitt P; Oertel W; Quinn N; Sethi K; Stocchi F
    Mov Disord; 2005 Jun; 20(6):726-33. PubMed ID: 15719426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia.
    Sitek EJ; Sołtan W; Wieczorek D; Schinwelski M; Robowski P; Reilmann R; Guzińska K; Harciarek M; Krysa W; Sławek J
    J Int Neuropsychol Soc; 2011 Sep; 17(5):788-95. PubMed ID: 21729402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the motor complications of Parkinson's disease on the quality of life.
    Chapuis S; Ouchchane L; Metz O; Gerbaud L; Durif F
    Mov Disord; 2005 Feb; 20(2):224-30. PubMed ID: 15384126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioural and neuroimaging correlates of impaired self-awareness of hypo- and hyperkinesia in Parkinson's disease.
    Maier F; Williamson KL; Tahmasian M; Rochhausen L; Ellereit AL; Prigatano GP; Kracht L; Tang CC; Herz DM; Fink GR; Timmermann L; Eggers C
    Cortex; 2016 Sep; 82():35-47. PubMed ID: 27341471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of electroconvulsive therapy in Parkinson disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study.
    Pintor LP; Valldeoriola F; Fernández-Egea E; Sánchez R; Rami L; Tolosa E; Muñiz A; Martí MJ; Bernardo M
    J ECT; 2012 Jun; 28(2):87-91. PubMed ID: 22531200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pain intensity on and off levodopa in patients with Parkinson's disease.
    Nebe A; Ebersbach G
    Mov Disord; 2009 Jun; 24(8):1233-7. PubMed ID: 19412949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.